The effects of zoledronic acid on serum sclerostin levels in patients with postmenopausal osteoporosis

Trial Profile

The effects of zoledronic acid on serum sclerostin levels in patients with postmenopausal osteoporosis

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2013

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 19 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top